ResMed (RMD) Tops Q2 EPS by 1c

January 27, 2011 4:23 PM EST
ResMed (NYSE: RMD) reported Q2 EPS of $0.37, $0.01 better than the analyst estimate of $0.36. Revenue for the quarter came in at $306 million versus the consensus estimate of $307.6 million.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Add Your Comment